ClinConnect ClinConnect Logo
Search / Trial NCT00567073

Pompe Pregnancy Sub-Registry

Launched by GENZYME, A SANOFI COMPANY · Dec 1, 2007

Trial Information

Current as of July 01, 2025

Recruiting

Keywords

Glycogen Storage Disease Type Ii (Gsd Ii) Gsd Ii Pompe Disease Pompe Disease (Late Onset) Acid Maltase Deficiency Disease Glycogenosis Ii

ClinConnect Summary

**Summary of the Pompe Pregnancy Sub-Registry**

The Pompe Pregnancy Sub-Registry is a study aimed at understanding how pregnancy affects women with Pompe disease, which is a rare genetic condition that can lead to muscle weakness. This program tracks the experiences and outcomes of pregnant women who are already part of the Pompe Registry, whether or not they are receiving specific treatments for their condition. The goal is to gather important information about any complications during pregnancy and how the babies grow after birth. No new treatments or drugs will be given; instead, participants will receive the usual care from their doctors.

To join this study, women must be enrolled in the Pompe Registry and currently be pregnant, or have been pregnant in the past, with the necessary medical documentation. They need to agree to participate by signing consent forms. It's important to note that there are no exclusions based on health conditions, so any woman who meets the criteria can participate. This study is a valuable opportunity for women with Pompe disease to contribute to our understanding of how their condition interacts with pregnancy, helping improve care and outcomes for others in the future.

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • Eligible women must:
  • be enrolled in the Pompe registry (NCT00231400)
  • be pregnant, or have been pregnant with appropriate medical documentation available.
  • provide a signed informed consent and authorization form(s) to participate in the Sub-Registry prior to any Sub-Registry-related data collection being performed.
  • Note: It is recommended that pregnancy data be collected on eligible women regardless of infant enrollment. In the event of patients having multiple pregnancies, participation in this Sub-Registry is encouraged for each individual pregnancy.
  • Exclusion Criteria:
  • There are no exclusion criteria for this Sub-Registry

About Genzyme, A Sanofi Company

Genzyme, a Sanofi company, is a global leader in biotechnology dedicated to developing innovative therapies for rare and complex diseases. With a strong focus on patient-centric solutions, Genzyme leverages advanced research and development capabilities to address unmet medical needs across various therapeutic areas, including neurology, oncology, and genetic disorders. Committed to scientific excellence and collaboration, Genzyme aims to improve patient outcomes through the discovery and commercialization of high-quality biopharmaceuticals, while upholding the highest standards of safety and efficacy in clinical trials.

Locations

Zagreb, , Croatia

Zagreb, , Croatia

Brescia, , Italy

Cagliari, , Italy

Firenze, , Italy

Genova, , Italy

Messina, , Italy

Milano, , Italy

Monza, , Italy

Padova, , Italy

Padova, , Italy

Pavia, , Italy

Roma, , Italy

Roma, , Italy

New York, New York, United States

Fairfax, Virginia, United States

Brescia, , Italy

Cagliari, , Italy

Firenze, , Italy

Genova, , Italy

Messina, , Italy

Milano, , Italy

Monza, , Italy

Padova, , Italy

Padova, , Italy

Pavia, , Italy

Roma, , Italy

Roma, , Italy

Indianapolis, Indiana, United States

New York, New York, United States

Durham, North Carolina, United States

Dublin, Ohio, United States

Grand Rapids, Michigan, United States

Fairfax, Virginia, United States

New York, New York, United States

Phoenix, Arizona, United States

Atlanta, Georgia, United States

Portland, Oregon, United States

Gent, , Belgium

Zagreb, , Croatia

Zagreb, , Croatia

Indianapolis, Indiana, United States

Grand Rapids, Michigan, United States

New York, New York, United States

New York, New York, United States

Durham, North Carolina, United States

Dublin, Ohio, United States

Fairfax, Virginia, United States

Brescia, , Italy

Cagliari, , Italy

Firenze, , Italy

Genova, , Italy

Messina, , Italy

Milano, , Italy

Monza, , Italy

Padova, , Italy

Padova, , Italy

Pavia, , Italy

Roma, , Italy

Roma, , Italy

Phoenix, Arizona, United States

Atlanta, Georgia, United States

Portland, Oregon, United States

Gent, , Belgium

Praha, , Czechia

Indianapolis, Indiana, United States

New York, New York, United States

Durham, North Carolina, United States

Dublin, Ohio, United States

Grand Rapids, Michigan, United States

Fairfax, Virginia, United States

New York, New York, United States

Portland, Oregon, United States

Milan, , Italy

Padua, , Italy

Phoenix, Arizona, United States

Atlanta, Georgia, United States

Patients applied

0 patients applied

Trial Officials

Study Director

Study Director

Genzyme, a Sanofi Company

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials